Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Australis Capital's share price for the quarter that ended in Dec. 2021 was $0.13575. Australis Capital's Shares Outstanding (EOP) for the quarter that ended in Dec. 2021 was 278.28 Mil. Therefore, Australis Capital's market cap for the quarter that ended in Dec. 2021 was $37.78 Mil.
Australis Capital's quarterly market cap
declined
from Jun. 2021 ($58.93 Mil) to Sep. 2021 ($38.76 Mil) and
declined
from Sep. 2021 ($38.76 Mil) to Dec. 2021 ($37.78 Mil).
Australis Capital's annual market cap
declined
from Mar. 2019 ($70.02 Mil) to Mar. 2020 ($22.73 Mil) but then
increased
from Mar. 2020 ($22.73 Mil) to Mar. 2021 ($56.85 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Australis Capital's Enterprise Value for Today is $0.00 Mil.
Australis Capital (OTCPK:AUSAF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Australis Capital Market Cap Related Terms
Australis Capital Market Cap Historical Data
* Premium members only.
The historical data trend for Australis Capital's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Australis Capital's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australis Capital Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Australis Capital's Market Cap distribution charts can be found below:
* The bar in red indicates where Australis Capital's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Australis Capital's Market Cap for the fiscal year that ended in Mar. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australis Capital (AUSAF) has a Market Cap of $0.00 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Australis Capital and its competitors.
Is Australis Capital's Market Cap too high?
Australis Capital's current Market Cap is $0.00 Mil.
How does Australis Capital's Market Cap compare to ZTS and CTLT?
Australis Capital's Market Cap of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 205.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 205.37, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Australis Capital and its competitors. For the Drug Manufacturers industry, the median Market Cap is 205.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australis Capital's current Market Cap is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australis Capital stock overvalued right now?
Australis Capital (AUSAF) has a current Market Cap of $0.00 Mil. The current Market Cap is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Australis Capital (AUSAF), the current Market Cap is $0.00 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Australis Capital Inc operates as a multi-state operator in the cannabis industry in the US. The company is focused on brands and attractive cannabis licenses in states with favorable economics. AUSA is building an MSO based on a unique and very difficult to imitate strategy. Secure access to low-cost but high-quality biomass enables the company to fuel the expansion of its footprint across the US. The company has a rapidly growing footprint in the U.S. in states, such as California, Nevada, Massachusetts, Missouri, Oklahoma, as well as international operations through its subsidiary ALPS, with projects in Europe, Asia and North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUSAF has been successfully added to your 